Cord Blood Serum in the Treatment of Ocular Surface Diseases
|ClinicalTrials.gov Identifier: NCT01234623|
Recruitment Status : Completed
First Posted : November 4, 2010
Last Update Posted : May 26, 2011
Human autologous serum (AS) eye drops have been successfully used in the treatment of severe ocular surface disorders and the enhancement of corneal wound healing, due to their growth factor (GF) content. Umbilical cord serum (UCS) contains even higher GF concentrations and the objective of the study was to prove whether UCS eye drops
- are effective in the healing of corneal epithelial defects.
- ameliorate the painful subjective symptoms
|Condition or disease||Intervention/treatment|
|Graft vs Host Disease Sjogren's Disease||Other: UCS eyedrops|
Hide Detailed Description
The regular collection and banking of cord blood remaining in the placenta after baby's delivery started in the early 1990s and was prompted by the observation that cord blood shows an immunological immaturity which allows to avoid any matching between donor-mother source and patient-recipient, it contains a number of haemopoietic progenitor and stem cells and is therefore potentially and safely useful in the field of regenerative medicine.
Cord blood collection occurs after the umbilical cord has been cut and is extracted from the fetal end of the cord. After collection, the cord blood unit bag is delivered to the lab, processed and then cryopreserved.
The main current clinical use of cord blood is allogeneic transplantation in patients suffering from severe blood diseases but physicians and researchers are making significant progresses evaluating the safety and efficacy of umbilical cord blood stem cells for therapeutic uses far beyond their uses for blood disorders.
Umbilical cord serum (UCS) contains many growth factors and especially EGF and TGF-beta1 concentrations are two-three times higher than in peripheral blood serum and much higher than in tears and is sufficient to prevent squamous metaplasia. In addition, UCS contains anti-inflammatory cytokines with protective effect.
Current therapy for SS-I and GVHD related dry eye depends upon clinical severity of the disease. From mild to progressively severe involvement of corneal epithelial damage , tear substitutes, FANS, steroids, Cyclosporin A, contact lens shields can be topically applied alone or in combination. Autologous serum eyedrops can be an option in severe cases as well, since it supplies epithelial growth factors to the healing process of epithelium.
The use of autologous serum eyedrops, however, is a controversial issues in diseases where inflammatory cytokines are present in peripheral blood, such as GVHD.
The use of cord blood serum based tear substitutes has been recently proposed in the literature for the treatment of ocular surface diseases and neurotrophic keratitis, because it contains growth factors, neurotrophic factors and essential components of tears. Moreover, serum from cord blood is readily available from cord blood banks as quality controlled product and is therefore theoretically attractive for topical use in ophthalmology.
The use of cord blood serum eyedrops as a biological preparation can display in itself efficacy features higher than the other drugs in terms of healing and anti-inflammatory properties in absence of any chemical compound.
In Italy biological products for topical use in ophthalmology to treat corneal epithelial severe defects are not available. The originality of the present study is based on the optimization and standardization of biological eyedrops prepared from cord blood serum. The efficacy and safety of the product for topical use in ocular surface diseases will be evaluated .
For the purpose, the following methods will be applied at baseline and endpoint (28 days of treatment with UCS eyedrops):
- Patients' subjective symptoms evaluation by a validated questionnaire for dry eye (OSDI)
- Slit Lamp examination and evaluation of Tear Film Break Up Time, corneal fluorescein staining score, conjunctival lissamine green staining score, staining will be recorded with digital photos to estimate the healing area in the follow up
- Schirmer I test to evaluate tear production
- Corneal sensitivity test (measured with a Cochet-Bonnet esthesiometer)
- Tear osmolarity, (TearLab, TearLab S.Diego) an indicator of the ability of the patient to compensate
- Tear Clearance Rate, a global indicator of tear production and tear evaporation
- Tear Proteomic to evaluate tear protein profile
- Corneal and Conjunctival inflammatory marker evaluation on cells collected by imprint and scraping cytology
Data will be statistically evaluated after 28 days treatment and matched vs baseline by using the descriptive statistics for paired data. Statistic outcomes will be analyzed with caution due to the non-randomized study design.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Pilot Phase. Cord Blood Serum in the Treatment of Ocular Surface Diseases|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||May 2011|
UCB eyedrops, single arm
One-centre pilot study, open, non randomized.
Other: UCS eyedrops
1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
Other Name: no brand names, serial or code numbers
- Corneal epithelial damage evaluated by fluorescein staining (micron meter squares) with digital photos [ Time Frame: 28 days treatment ]Digital photographs taken at the slit lamp will be evaluated by means of an Image Analyzer softare, to determine the area of corneal epithelial damage involved at a given stand point. Reduction of damaged area will be estimated in micron meter squares
- Reduction the patients' painful subjective symptoms [ Time Frame: 28 days treatment ]Subjective symptoms will be evaluated by means of a validated Questionnaire (OSDI, Ocular Surface Disease Index) at the given stand points
- Reduction the patients' painful subjective symptoms [ Time Frame: 15 days treatment ]Subjective symptoms will be evaluated by means of a validated Questionnaire (OSDI, Ocular Surface Disease Index) at the given stand points
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01234623
|Ophthalmology Unit, Dept.of Specialistic Surgery and Anesthesiological Sciences|
|Bologna, Italy, 40138|
|Study Director:||Emilio C Campos, MD||Head of Ophthalmology Unit, Dept.of Specialistic Surgery and Anesthesiological Sciences, University of Bologna, Policlinico S. Orsola-Malpighi, Pad 1 Palagi, Via Palagi 9 -40138 Bologna Italy|